A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
This study has been completed.
Information provided by:
First received: March 27, 2006
Last updated: May 24, 2013
Last verified: May 2013
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
Type 2 Diabetes
Drug: MK0954, losartan / Duration of Treatment: mean 3.4 years
Drug: Placebo / Duration of Treatment: mean 3.4 years
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- Combined endpoint of doubling of serum creatinine, ESRD or death.
Secondary Outcome Measures:
- Secondary parameters: number of cardiovascular events and changes in proteinuria. Tertiary parameters: quality of life and healthcare resource utilization.
|Study Start Date:||June 1996|
|Primary Completion Date:||April 2001 (Final data collection date for primary outcome measure)|
Contacts and Locations